MicroRNA signatures predict prognosis of patients with glioblastoma multiforme through the Cancer Genome Atlas

MicroRNAs (miRNAs) play major roles in various biological processes and have been implicated in the pathogenesis and malignant progression of glioblastoma multiforme (GBM). The aim of this study was to assess the predictive values of miRNAs for overall survival (OS) of patients with GBM. MiRNA expression profiles and clinical information of 563 GBM patients were obtained from the Cancer Genome Atlas. The most significantly altered miRNAs were identified and miRNA expression profiles were performed, through principal component analysis, the least absolute shrinkage and selection operator method. The survival analysis was performed using the Cox regression models. Additionally, receiver operating characteristic (ROC) analysis was used to assess the performance of survival prediction. We used the bioinformatics tools to establish the miRNA signature for biological relevance assessment. A linear prognostic model of three miRNAs was developed and the patients were divided into high risk and low risk groups based this model. The area under the ROC curve (AUC) for the three miRNA signature predicting 5-year survival was 0.894 (95%CI, 0.789-1.000) in the testing set and0.841 (95%CI, 0.689-0.993) in all GBM patients. High risk patients had significantly shorter OS than patients with low risk (P< 0.001). The results from this study support a three miRNA signature for outcome prediction of GBM. These results provided a new prospect for prognostic biomarker of GBM.

[1]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[2]  Stefano Volinia,et al.  Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer , 2013, Proceedings of the National Academy of Sciences.

[3]  Chang-Zheng Chen,et al.  MicroRNAs as oncogenes and tumor suppressors. , 2005, The New England journal of medicine.

[4]  Hui Li,et al.  Identification of a seven-miRNA signature as prognostic biomarker for lung squamous cell carcinoma , 2016, Oncotarget.

[5]  K. Kelnar,et al.  The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. , 2011, Nature medicine.

[6]  Xiaoning Peng,et al.  An Integrated mRNA and microRNA Expression Signature for Glioblastoma Multiforme Prognosis , 2014, PloS one.

[7]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[8]  Longyang Jiang,et al.  MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1) , 2016, Journal of Experimental & Clinical Cancer Research.

[9]  Wei Li,et al.  Downregulated miR-646 in clear cell renal carcinoma correlated with tumour metastasis by targeting the nin one binding protein (NOB1) , 2014, British Journal of Cancer.

[10]  L. Chin,et al.  miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma , 2015, Genes & development.

[11]  J. Cheng,et al.  MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma , 2010, Molecular Cancer.

[12]  E. Sontheimer,et al.  Origins and Mechanisms of miRNAs and siRNAs , 2009, Cell.

[13]  Jian Zhao,et al.  Four microRNAs Signature for Survival Prognosis in Colon Cancer using TCGA Data , 2016, Scientific Reports.

[14]  I. Lorimer,et al.  Regulation of p27Kip1 by miRNA 221/222 in Glioblastoma , 2007, Cell cycle.

[15]  Longyang Jiang,et al.  miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells. , 2016, Gynecologic oncology.

[16]  M. Bhasin,et al.  MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis. , 2014, Cell stem cell.

[17]  Y. Tu,et al.  MicroRNA-101 inhibits proliferation, migration and invasion of human glioblastoma by targeting SOX9 , 2016, Oncotarget.

[18]  Jun Zhang,et al.  miRNA-646 suppresses osteosarcoma cell metastasis by downregulating fibroblast growth factor 2 (FGF2) , 2015, Tumor Biology.

[19]  C. Bai,et al.  miR-646 is a key negative regulator of EGFR pathway in lung cancer , 2016, Experimental lung research.

[20]  K. Oguchi,et al.  Reduced PTEN expression and overexpression of miR-17-5p, -19a-3p, -19b-3p, -21-5p, -130b-3p, -221-3p and -222-3p by glioblastoma stem-like cells following irradiation. , 2015, Oncology letters.

[21]  C. Kang,et al.  Global changes of mRNA expression reveals an increased activity of the interferon-induced signal transducer and activator of transcription (STAT) pathway by repression of miR-221/222 in glioblastoma U251 cells. , 2010, International journal of oncology.

[22]  O. Mariani,et al.  miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response , 2011, Nature Medicine.

[23]  Guang-Yuh Chiou,et al.  Epigenetic regulation of the miR142-3p/interleukin-6 circuit in glioblastoma. , 2013, Molecular cell.

[24]  V. del Vescovo,et al.  microRNA and Lung Cancer. , 2015, Advances in experimental medicine and biology.

[25]  H. H. Andersen,et al.  A Systematic Review of MicroRNA in Glioblastoma Multiforme: Micro-modulators in the Mesenchymal Mode of Migration and Invasion , 2012, Molecular Neurobiology.

[26]  C. Zhang,et al.  miR-221/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status. , 2014, Current molecular medicine.

[27]  P. Royston,et al.  Selection of important variables and determination of functional form for continuous predictors in multivariable model building , 2007, Statistics in medicine.

[28]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[29]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[30]  Hao Jiang,et al.  Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. , 2009, International journal of oncology.

[31]  R. S. Huang,et al.  Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas , 2016, PloS one.

[32]  L. Chin,et al.  Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.

[33]  Xuerui Yang,et al.  An Extensive MicroRNA-Mediated Network of RNA-RNA Interactions Regulates Established Oncogenic Pathways in Glioblastoma , 2011, Cell.

[34]  Andrea Sottoriva,et al.  The shaping and functional consequences of the microRNA landscape in breast cancer , 2013, Nature.

[35]  K. Obrietan,et al.  Revealing a Role of MicroRNAs in the Regulation of the Biological Clock , 2007, Cell cycle.

[36]  H. Park,et al.  MicroRNA-302 induces proliferation and inhibits oxidant-induced cell death in human adipose tissue-derived mesenchymal stem cells , 2014, Cell Death and Disease.

[37]  H. H. Andersen,et al.  MicroRNA Expression Signatures Determine Prognosis and Survival in Glioblastoma Multiforme—a Systematic Overview , 2014, Molecular Neurobiology.

[38]  G. Maira,et al.  Extensive modulation of a set of microRNAs in primary glioblastoma. , 2005, Biochemical and biophysical research communications.

[39]  A. Órfão,et al.  Molecular and Genomic Alterations in Glioblastoma Multiforme. , 2015, The American journal of pathology.

[40]  Sung-Liang Yu,et al.  MicroRNA signature predicts survival and relapse in lung cancer. , 2008, Cancer cell.

[41]  M. Duroux,et al.  MicroRNA Expression Signatures and Their Correlation with Clinicopathological Features in Glioblastoma Multiforme , 2014, NeuroMolecular Medicine.

[42]  M. Lotze,et al.  Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1 , 2009, Proceedings of the National Academy of Sciences.

[43]  M. Esteller,et al.  miR-221/222 Target the DNA Methyltransferase MGMT in Glioma Cells , 2013, PloS one.

[44]  Tae-Min Kim,et al.  A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. , 2011, Cancer research.

[45]  C. Kang,et al.  miR-221/222 promote malignant progression of glioma through activation of the Akt pathway. , 2010, International journal of oncology.

[46]  Sujaya Srinivasan,et al.  A Ten-microRNA Expression Signature Predicts Survival in Glioblastoma , 2011, PloS one.

[47]  K. Kosik,et al.  MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. , 2005, Cancer research.

[48]  A. Yeganeh,et al.  RETRACTED ARTICLE: Downregulation of microRNA-217 and microRNA-646 acts as potential predictor biomarkers in progression, metastasis, and unfavorable prognosis of human osteosarcoma , 2016, Tumor Biology.